BrainsWay raises FY 2026 revenue guidance to $68 mln-$70 mln from $66 mln-$68 mln
Company lifts FY 2026 adjusted EBITDA outlook to $13 mln-$14 mln from $12 mln-$14 mln
BrainsWay expects FY 2026 operating income margin of 13.5%-14%
Growth drivers
Record system shipments - Company shipped a record 125 Deep TMS systems in Q2, up 42% year over year
Expanding insurer coverage - Company said growth was fueled by expanding reimbursement coverage for SWIFT protocol
Higher utilization - Company cited increasing utilization throughout its installed base as a growth driver
Analyst coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Brainsway Ltd is $18.00, about 20.2% above its August 11 closing price of $14.98
BWAY•
